

Correction No. 1 made to the List of Medications in effect on 30 September 2020

An Act respecting prescription drug insurance
(chapter A-29.01, s. 60, 7th para. and s. 60.2)

In accordance with section 60.2 of the Act respecting prescription drug insurance, the Régie de l'assurance maladie du Québec (the Régie) has made the required corrections to the List of Medications, attached to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan (CQLR, chapter A-29.01, r. 3), which came into force on 30 September 2020. Under this section, these corrections may come into effect on the effective date of the coming into force of the price decrease or on the effective date of the coming into force of the provision for which the correction was requested.

To this end, the Régie has corrected the price decrease for Ruxience 10 ml and 50 ml (10 mg/mL) with respect to the cost of its package sizes:

Code	Brand name	Manufacturer	Package size	Cost of package size indicated	Corrected cost of package size
02495724	Ruxience	Pfizer	10 ml 50 ml	313.50 1 567.51	297.00 1 485.00

As well, the Régie was informed of an obvious clerical error with respect to Nivestym Inj. Sol. 300 mcg/mL (1.0 mL) and Nivestym Inj. Sol. (syr) 600 mcg/mL (0.5 mL) for which a correction to the identification number is required:

Code indicated	Corrected code	Brand name	Manufacturer	Package size	Dosage form	Strength
02485575	02485591	Nivestym	Pfizer	10	Inj. Sol.	300 mcg/mL (1.0 mL)
02485591	02485575	Nivestym	Pfizer	1 10	Inj. Sol. (syr)	600 mcg/mL (0.5 mL)

These corrections take effect from 30 September 2020.

Publication of these corrections on the website of the Régie imparts authentic value to them, in accordance with the last paragraph of section 60 of the Act respecting prescription drug insurance.

Québec, 2 octobre 2020

[Original signed by]

MARCO THIBAUT
President and Chief Executive Officer
Régie de l'assurance maladie du Québec